in the United States dedicated solely to mental health. Janssen currently markets prescription medications for the treatment of schizophrenia, Bipolar 1 Disorder, and schizoaffective disorder. Ortho-McNeil-Janssen Pharmaceuticals, Inc., is a member of the Johnson & Johnson Family of Companies. For more information about Janssen, visit http://www.janssen.com
About Patriot Pharmaceuticals, LLCPatriot Pharmaceuticals, LLC is a wholly owned subsidiary of Ortho-McNeil-Janssen Pharmaceuticals, Inc. The company markets and distributes authorized generic pharmaceuticals, including itraconazole, ketoconazole, galantamine, Tramadol HCl ER 100mg and 200mg and risperidone. Patriot is located in Horsham, PA.
Important Safety Information About RISPERDAL® and Risperidone Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. RISPERDAL® (risperidone) is not approved for the treatment of patients with dementia-related psychosis.
The most common adverse reactions observed in all clinical trials with RISPERDAL® occurring at a rate of at least 10% were drowsiness, increased appetite, fatigue, insomnia, sedation, tremor, muscle stiffness , vomiting, coughing, constipation, stuffy nose, runny nose, drooling, dry mouth, abdominal pain, dizziness, nausea, anxiety, headache, nasal congestion , common cold, rash, and restlessness.
Neuroleptic Malignant Syndrome (NMS) is a rare and potentially fatal side effect reported with RISPERDAL® and similar medicines. Call your doctor immediately if the person being treated develops symptoms such as high fever; stiff muscles; shaking; confusion; sweating; changes in pulse, heart rate, or blood pressure; or muscle pain and weakness. Treatment should be stopped if the person being treated has
Page: 1 2 3 4 5 6 7 Related medicine technology :1
|SOURCE Ortho-McNeil-Janssen Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Announces Oncology Research Collaboration Agreement with the Koch Institute for Integrative Cancer Research at MIT2
. The Pittsburgh Life Sciences Greenhouse Congratulates Diamyd Medical on Its Agreement with Ortho-McNeil-Janssen Pharmaceuticals to Develop Diabetes Therapy3
. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Resolves Investigation of Past TOPAMAX(R) Marketing and Promotional Activities4
. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Agrees to $75 Million Settlement for Topamax(R) False Claims Lawsuit5
. AUDIO from Medialink and Ortho-McNeil-Janssen Pharmaceuticals Inc.: Getting Ready for Cold and Flu Season6
. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals7
. Omthera Pharmaceuticals, Inc. to Present at the 2011 Wells Fargo Securities Healthcare Conference8
. Pacira Pharmaceuticals, Inc. Announces FDA Extension of EXPAREL™ PDUFA Target Date by Three Months9
. Ampio Pharmaceuticals, Inc. Appoints New Independent Director10
. Aeolus Pharmaceuticals, Inc. Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com11
. Pacira Pharmaceuticals, Inc. Appoints Two Life Sciences Industry Veterans to Its Board of Directors